Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGFBP5 | P24593 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | IGFBP3 | P17936 | 4/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | PPM1G | O15355 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | PPM1A | P35813 | 1/20 | 0.32 |
| ▸ | PTPN9 | P43378 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384232 | 0.84 | IGFBP3 (0.41) | IGFBP5ALOX15TSHRHIF1AIGFBP3 | |
| SCHEMBL158714 | 0.84 | IGFBP3 (0.41) | IGFBP5ALOX15TSHRHIF1AIGFBP3 | |
| Water SCHEMBL17596689 | 0.83 | IGFBP3 (0.40) | IGFBP5ALOX15TSHRHIF1AIGFBP3 | |
| Water SCHEMBL30546266 | 0.83 | IGFBP3 (0.40) | IGFBP5ALOX15TSHRHIF1AIGFBP3 | |
| SCHEMBL13037420 | 0.81 | IGFBP5 (0.35) | IGFBP5ALOX15TSHRHIF1AIGFBP3 | |
| 7-Chlorokynurenic Acid SCHEMBL157187 | 0.71 | IGFBP3 (0.47) | IGFBP5HIF1AIGFBP3KMOPTGES | |
| 7-Chlorokynurenic Acid SCHEMBL29386783 | 0.71 | IGFBP3 (0.47) | IGFBP5HIF1AIGFBP3KMOPTGES | |
| SCHEMBL9463397 | 0.71 | AKR1C4 (0.44) | ALOX15TSHRIGFBP3GPR35PTGES | |
| 7-Chlorokynurenic Acid SCHEMBL31238955 | 0.71 | IGFBP3 (0.47) | IGFBP5HIF1AIGFBP3KMOPTGES | |
| SCHEMBL7524860 | 0.70 | KDM4E (0.44) | IGFBP5ALOX15TSHRIGFBP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995028081-A1 | ADDRESSING BAIT AVERSION BY DISRUPTING ASSOCIATIVE LEARNING | THE MEAT INDUSTRY RESEARCH INSTITUTE OF NEW ZEALAND INC. (NZ) | 1995-10-26 | — | — | WO | claimed |
| EP-3056200-B1 | HUPERZINE FOR USE IN TREATING SEIZURE | HARVARD COLLEGE (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3056200-A2 | HUPERZINE FOR USE IN TREATING SEIZURE, PAIN, ORTHOSTATIC HYPOTENSION OR VERTIGO | President and Fellows of Harvard College (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-1901733-B1 | HUPERZINE FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | HARVARD COLLEGE (US) | 2016-04-06 | — | — | EP | disclosed |
| US-8822492-B2 | Use of huperzine for disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-02 | — | — | US | disclosed |
| US-8193212-B2 | Use of huperzine for neuropathic pain | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120107392-A1 | USE OF HUPERZINE FOR DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-05-03 | — | — | US | disclosed |
| US-8093262-B2 | Use of huperzine for disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110224245-A1 | Treatment Of Neurological Disorders Using Huperzine | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2328584-A2 | TREATMENT OF NEUROLOGICAL DISORDERS USING HUPERZINE | President and Fellows of Harvard College (US) | 2011-06-08 | — | — | EP | disclosed |
| US-5925634-A | Use of ibogaine for treating neuropathic pain | WASHINGTON UNIVERSITY (US) | 1999-07-20 | — | — | US | disclosed |
| US-5902815-A | REDUCING NEUROLOGICAL SIDE EFFECTS OF N-METHYL-D-ASPARTATE ANTAGONISTS | WASHINGTON UNIVERSITY (US) | 1999-05-11 | — | — | US | disclosed |
| US-5877173-A | CLOZAPINE, OLANZAPINE AND FLUPERLAPINE, AND SALTS, ISOMERS AND ANALOGS THEREOF, IS ADMINISTERED. | WASHINGTON UNIVERSITY (US) | 1999-03-02 | — | — | US | disclosed |
| US-5767130-A | Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists | OLNEY JOHN W (US) | 1998-06-16 | — | — | US | disclosed |
| US-5629307-A | Use of ibogaine in reducing excitotoxic brain damage | OLNEY JOHN W (US) | 1997-05-13 | — | — | US | disclosed |
| US-5629336-A | Use of glycine/NMDA receptor ligands for the treatment of drug dependence and withdrawal | MERCK, SHARP & DOHME LTD. (GB) | 1997-05-13 | — | — | US | disclosed |
| US-5605911-A | NEUROTOXIC SIDE EFFECT INHIBITION | WASHINGTON UNIVERSITY (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0514023-B1 | Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal | MERCK SHARP & DOHME (GB) | 1996-03-20 | — | — | EP | disclosed |
| WO-1995028081-A1 | ADDRESSING BAIT AVERSION BY DISRUPTING ASSOCIATIVE LEARNING | THE MEAT INDUSTRY RESEARCH INSTITUTE OF NEW ZEALAND INC. (NZ) | 1995-10-26 | — | — | WO | disclosed |
| EP-0514023-A1 | Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal | MERCK SHARP & DOHME LTD. (GB) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224245-A1 | Treatment Of Neurological Disorders Using Huperzine | GAP43, ACHE, NCS1 | IGFBP5 2315/4885ALOX15 706/4885TSHR 4307/4885 |
| US-20120107392-A1 | USE OF HUPERZINE FOR DISORDERS | HCN1, HCN2, ACHE | IGFBP5 1891/4885ALOX15 806/4885TSHR 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.